Y
Yutaka Shimada
Researcher at University of Toyama
Publications - 445
Citations - 15929
Yutaka Shimada is an academic researcher from University of Toyama. The author has contributed to research in topics: Cancer & Esophageal cancer. The author has an hindex of 58, co-authored 441 publications receiving 14980 citations. Previous affiliations of Yutaka Shimada include Kyoto University & Niigata University.
Papers
More filters
Journal ArticleDOI
Herbal medicine and false-positive results on lymphocyte transformation test.
Naoki Mantani,Shinya Sakai,Toshiaki Kogure,Hirozo Goto,Naotoshi Shibahara,Toshiaki Kita,Yutaka Shimada,Katsutoshi Terasawa +7 more
TL;DR: Mitogenic activity inherent to some herbs and Kampo formulae may sometimes cause false-positivity on LTT in clinical situations, and this suggests that LTT for KampoFormula may be unreliable as a diagnostic method for drug-induced liver injury.
Journal ArticleDOI
Synchronous asymptomatic colonic metastasis from primary esophageal squamous cell carcinoma
Yutaka Shimada,Yutaka Shimada,Tomoyuki Okumura,Shozo Hojo,Kenta Sukegawa,Takuya Nagata,Shinichi Hayashi,Kazuhiro Tsukada +7 more
TL;DR: The findings suggest that even with well-controlled and asymptomatic colonic metastasis from primary esophageal lesions, the prognosis of patients with primary ESCC is poor.
Journal ArticleDOI
Impact of neoadjuvant chemotherapy on Ki-67 and PCNA labeling indices for esophageal squamous cell carcinomas.
Naotoshi Horii,Yasumasa Nishimura,Y. Okuno,Shuichi Kanamori,Masahiro Hiraoka,Yutaka Shimada,Masayuki Imamura +6 more
TL;DR: Neoadjuvant CT decreased the percentage of cycling and proliferative tumor cells of esophageal cancer and significant correlation of Ki-67 and PCNA LIs between biopsy and surgical specimens was demonstrated for the control group.
Journal ArticleDOI
Induction of human leukocyte antigen (HLA)-A2-restricted and MAGE-3-gene-derived peptide-specific cytolytic T lymphocytes using cultured dendritic cells from an HLA-A2 esophageal cancer patient.
Shunji Kanaoka,Seiji Yamasaki,Takashi Okino,Naoya Inoue,Yutaka Shimada,Midori Kaneko,Akira Otaka,Nobutaka Fujii,Masayuki Imamura +8 more
TL;DR: Using peripheral blood mononuclear cells from a 10‐year survivor with established human leukocyte antigen (HLA)‐A2(+) and MAGE‐3(+) esophageal cancer cell line (KYSE‐170), the induction of HLA‐A 2‐restricted and Mage‐3‐gene‐derived peptide (FLWGPRALV, amino acids 271–279)‐specific cytolytic T lymphocytes (CTLs).
Journal ArticleDOI
Challenge Tests and Kampo Medicines: Case Report and Review of the Literature
TL;DR: A challenge with a small dose of Kampo medicine conducted in this case and in the previous literature induced mild and reversible liver injury.